Carboplatin plus Paclitaxel in Combination with the Histone Deacetylate Inhibitor, Vorinostat, in Patients with Recurrent Platinum-Sensitive Ovarian Cancer
<b>Background:</b> This phase II study evaluated the efficacy and safety of the histone deacetylase (HDAC) inhibitor, vorinostat, administered in combination with paclitaxel and carboplatin in patients with platinum sensitive recurrent ovarian cancer. <b>Methods:</b> Women wi...
Main Authors: | Hanieh Meteran, Anja Ør Knudsen, Trine Lembrecht Jørgensen, Dorte Nielsen, Jørn Herrstedt |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2024-02-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/13/3/897 |
Similar Items
-
Brief Report: Case Comparison of Therapy With the Histone Deacetylase Inhibitor Vorinostat in a Neonatal Calf Model of Pulmonary Hypertension
by: Tanya J. Applegate, et al.
Published: (2021-09-01) -
Vorinostat (SAHA) and Breast Cancer: An Overview
by: Anna Wawruszak, et al.
Published: (2021-09-01) -
Differential Response of Mycosis Fungoides Cells to Vorinostat
by: Zachary A. Bordeaux, et al.
Published: (2023-04-01) -
Quantitative Acetylomics Uncover Acetylation-Mediated Pathway Changes Following Histone Deacetylase Inhibition in Anaplastic Large Cell Lymphoma
by: Maša Zrimšek, et al.
Published: (2022-08-01) -
Effect of histone deacetylase inhibitor (vorinostat) on new-onset diabetes induced by tacrolimus
by: Fatmah A. Bakhdar, MSc, et al.
Published: (2023-02-01)